PerspectiveChromatin Therapeutics

Cancer Drug Discovery Faces the FACT

See allHide authors and affiliations

Science Translational Medicine  10 Aug 2011:
Vol. 3, Issue 95, pp. 95ps34
DOI: 10.1126/scitranslmed.3002822

You are currently viewing the abstract.

View Full Text


In this issue of Science Translational Medicine, Gasparian et al. use a clever cell-based screen to identify a family of DNA-binding small molecules—curaxins—that inhibit tumor cell growth and division. The curaxins’ mechanism of action pinpoints a new chromatin-remodeling factor as a therapeutic target for cancer.


  • Citation: G. F. Draetta, R. A. DePinho, Cancer Drug Discovery Faces the FACT. Sci. Transl. Med. 3, 95ps34 (2011).

View Full Text